Home › Bronchiolitis Obliterans Syndrome › North Carolina › Charlotte
Bronchiolitis Obliterans Syndrome clinical trials in Charlotte, NC
4 studies for Bronchiolitis Obliterans Syndrome are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
RecruitingPhase 2
- Levine Cancer Institute, Charlotte
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
RecruitingObservational study
- Levine Cancer Institute, Charlotte
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
RecruitingPhase 3
- Levine Cancer Institute, Charlotte
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- Levine Cancer Institute, Charlotte
Bronchiolitis Obliterans Syndrome trials in other cities
- Boston, MA13 studies
- Seattle, WA11 studies
- Atlanta, GA10 studies
- New York City, NY9 studies
- Houston, TX8 studies
- Los Angeles, CA7 studies
- Miami, FL7 studies
- Durham, NC6 studies
- Tampa, FL6 studies
- Baldwin Park, CA6 studies
- Philadelphia, PA6 studies
- Washington, DC6 studies
Other studies in Charlotte
- Cancer (all types)27 studies
- Breast Cancer22 studies
- Multiple Myeloma21 studies
- Non-Small Cell Lung Cancer19 studies
- Acute Myeloid Leukemia16 studies
- Obesity16 studies
- Overweight15 studies
- Colorectal Cancer13 studies
- Ovarian Cancer12 studies
- Heart Failure11 studies
- Metastatic Cancer11 studies
- Head and Neck Squamous Cell Carcinoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.